Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01632137 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome
A Phase 3 study, sponsored by Kubota Vision.
- Completed
- Registry status
- Phase 3
- Development phase
- 564
- Enrollment target
NCT01632137 is a Phase 3 study that has completed, run by Kubota Vision. The registered enrollment target is 564 participants.
The verdict
NCT01632137, a Phase 3 study, has completed, sponsored by Kubota Vision.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 564 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of rebamipide ophthalmic suspension in subjects with dry eye syndrome.
Interventions
- DRUG Rebamipide 2% ophthalmic suspension
- DRUG Placebo (vehicle)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 564 participants |
| Start Date | 2012-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01632137
The ClinicalTrials.gov registry entry for NCT01632137 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 564 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kubota Vision, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rebamipide 2% ophthalmic suspension is the first listed.
NCT01632137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01632137 about?
NCT01632137 is a clinical study titled "Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome". The purpose of this study is to evaluate the efficacy and safety of rebamipide ophthalmic suspension in subjects with dry eye syndrome.
What is the current status of trial NCT01632137?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 564 participants. The study started on 2012-06.
What interventions are being tested in trial NCT01632137?
The interventions under investigation include: Rebamipide 2% ophthalmic suspension (DRUG), Placebo (vehicle) (DRUG).
Who is sponsoring clinical trial NCT01632137?
This trial is sponsored by Kubota Vision, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.